BRIDGEWATER, N.J.--(BUSINESS WIRE)--The National Institutes of Health (NIH), through the Small Business Innovation and Research (SBIR) Program, has awarded Neurotez, Inc. a $2.73-million dollar, three-year grant to initiate the clinical development of a Leptin product as a novel therapy for Alzheimer’s disease. Leptin, a naturally occurring human hormone associated with various metabolic effects, has a large number of receptors in memory centers of the brain and is often decreased in patients with Alzheimer’s disease. The Neurotez approach is based on restoration of Leptin levels.
